Epilepsy – Current Treatment – Detailed, Expanded Analysis – Treatment Algorithms – Claims Data Analysis (US)

Epilepsy is a heterogeneous condition requiring individualized treatment, and a substantial number of patients are treatment-refractory. Neurologists consider many factors when selecting an antiepileptic drug (AED) and must make adjustments throughout the patient’s disease course to achieve optimal seizure control. Understanding the evolving patient journey in epilepsy provides important context about the complex, saturated, and heavily generic market that developers of new AEDs will enter. We provide national patient-level claims data that show the use of key therapies in both newly diagnosed and recently treated patients, line of therapy progression, and persistence and compliance by brand.

QUESTIONS ANSWERED

  • · What patient shares do key therapies and brands garner by line of therapy in newly diagnosed epilepsy? What are the quarterly trends in prescribing among recently treated and newly diagnosed epilepsy patients?
  • How have Xcopri, Fintepla, Epidiolex, and other third-generation brands been integrated into the treatment algorithm, and what is their source of business?
  • What percentage of epilepsy patients receive drug therapy within two years of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within two years of diagnosis?
  • What percentage of epilepsy patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
  • What are the product-level compliance and persistency rates among drug-treated patients?

Markets covered: United States

Real-world data: Longitudinal patient-level claims data analysis.

Key companies: GW Pharmaceuticals, Eisai, Supernus Pharmaceuticals, Upsher-Smith, UCB, Sunovion, Pfizer.

Key drugs covered: Xcopri, Fintepla, Vimpat, Aptiom, Briviact, Epidiolex, Fycompa, Lyrica, levetiracetam, lamotrigine, carbamazepine and oxcarbazepine.

Key analysis provided:

  • Brand/therapy usage across a longitudinal patient sample.
  • Newly diagnosed patient analysis.
  • Treatment initiation and progression.
  • Line of therapy analysis.
  • Combination therapy analysis.
  • Source of business for recently treated patients.
  • Persistency and compliance analysis.
  • Product-level patient flowchart.

PRODUCT DESCRIPTION

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.

Solution Enhancement

The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and quarterly data refreshes.

Table of contents

  • Epilepsy - Current Treatment - Detailed, Expanded Analysis - Treatment Algorithms - Claims Data Analysis (US)
    • Treatment Algorithms CDA Epilepsy US May 2021
    • Treatment Algorithms CDA Epilepsy US 2021 Dashboard

launch Related Market Assessment Reports